The surgical prognosis of pIIIA/N2 non-small-cell lung cancers
- 20 Downloads
Abstract
Objective
The aim of the study was to identify prognostic factors in non-small-cell lung cancer (NSCLC) with N2 nodal involvement.
Methods
A retrospective analysis of disease free survival and 5-year survival for NSCLC patients who underwent primary surgical resection without neoadjuvant chemotherapy were performed. Between January 1998 and May 2004, 133 patients were enrolled. Several factors such as age, sex, skip metastasis, number of N2 lymph node stations, type of resection, histology, adjuvant therapy etc., were recorded and analyzed. SPSS 16.0 software was used.
Results
Overall 5-year survival for 133 patients was 32.33%, 5-year survival for single N2 station and multiple N2 stations sub-groups were 39.62% and 27.50% respectively, and 5-year survival for cN0–1 and cN2 sub-groups were 37.78% and 20.93% respectively. COX regression analysis revealed that number of N2 station (P = 0.013, OR: 0.490, 95% CI: 0.427–0.781) and cN status (P = 0.009, OR: 0.607, 95% CI: 0.372–0.992) were two favorable prognostic factors of survival.
Conclusion
Number of N2 station and cN status were two favorable prognostic factors of survival. In restrict enrolled circumstances, after combined therapy made up of surgery and postoperative adjuvant therapy have been performed, satisfied survival could be achieved.
Key words
non-small-cell lung cancer (NSCLC) N2 metastasis prognosisPreview
Unable to display preview. Download preview PDF.
References
- 1.National Cancer Institute. Surveillance, epidemiology and end results (SEER) data. http://seer.cancer.gov/. Accessed Jun 5, 2008.
- 2.van Meerbeeck JP, Kramer GW, Van Schil PE, et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst, 2007, 99: 442–450.CrossRefPubMedGoogle Scholar
- 3.Detterbeck F. What to do with “Surprise” N2?: intraoperative management of patients with non-small cell lung cancer. J Thorac Oncol, 2008, 3: 289–302.CrossRefPubMedGoogle Scholar
- 4.NCCN clinical practice guidelines in oncology. www.nccn.org. Nonsmall cell lung cancer. V2. 2009.
- 5.Mountain CF. Revisions in the international system for staging lung cancer. Chest, 1997, 111: 1710–1717.CrossRefPubMedGoogle Scholar
- 6.Robinson LA, Ruckdeschel JC, Wagner H Jr, et al. Treatment of nonsmall cell lung cancer — stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition). Chest, 2007, 132: 243S–265S.CrossRefPubMedGoogle Scholar
- 7.Friedel G, Steger V, Kyriss T, et al. Prognosis in N2 NSCLC. Lung cancer, 2004, 45Suppl 2: S45–53.CrossRefPubMedGoogle Scholar
- 8.Andre F, Grunenwald D, Pignon JP, et al. Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. J Clin Oncol, 2000, 18: 2981–2989.PubMedGoogle Scholar
- 9.Cerfolio RJ, Bryant AS, Eloubeidi MA. Routine mediastinoscopy and esophageal ultrasound fine-needle aspiration in patients with non-small cell lung cancer who are clinically N2 negative: a prospective study. Chest, 2006, 130: 1791–1795.CrossRefPubMedGoogle Scholar
- 10.Meyers BF, Haddad F, Siegel BA, et al. Cost-effectiveness of routine mediastinoscopy in computed tomography- and positron emission tomography-screened patients with stage I lung cancer. J Thorac Cardiovasc Surg, 2006, 131: 822–829.CrossRefPubMedGoogle Scholar
- 11.Ponn RB, LoCicero J 3rd, Daly BDT. Surgical treatment of non-cell lung cancer. Shields TW, LoCicero J III, Ponn RB, Rusch VW, eds. In: General thoracic surgery. 6th ed. Philadelphia, PA: Lippincott Williams and Wilkins, 2005. 1548–1587.Google Scholar
- 12.Rocco G. Results of cutting-edge surgery in stage IIIA-N2 nonsmall cell lung cancer. Curr Opin Oncol, 2009, 21: 105–109.CrossRefPubMedGoogle Scholar
- 13.Cerfolio RJ, Bryant AS. Survival of patients with unsuspected N2 (stage IIIA) nonsmall-cell lung cancer. Ann Thorac Surg, 2008, 86: 362–366.CrossRefPubMedGoogle Scholar
- 14.Saito M, Kato H. Prognostic factors in patients with pathological and N2 non-small cell lung cancer. Ann Thorac Cardiovasc Surg, 2008, 14: 1–2.PubMedGoogle Scholar
- 15.Riquet M, Bagan P, Le Pimpec Barthes F, et al. Completely resected non-small cell lung cancer: reconsidering prognostic value and significance of N2 metastases. Ann Thorac Surg, 2007, 84: 1818–1824.CrossRefPubMedGoogle Scholar
- 16.Misthos P, Sepsas E, Kokotsakis J, et al. The significance of one-station N2 disease in the prognosis of patients with nonsmall-cell lung cancer. Ann Thorac Surg, 2008, 86: 1626–1630.CrossRefPubMedGoogle Scholar
- 17.Riquet M, Assouad J, Bagan P, et al. Skip mediastinal lymph node metastasis and lung cancer: a particular N2 subgroup with a better prognosis. Ann Thorac Surg, 2005, 79: 225–233.CrossRefPubMedGoogle Scholar
- 18.Yamamoto K, Miyamoto Y, Ohsumi A, et al. Sleeve lung resection for lung cancer: analysis according to the type of procedure. J Thorac Cardiovasc Surg, 2008, 136: 1349–1356.CrossRefPubMedGoogle Scholar
- 19.Kang CH, Ra YJ, Kim YT, et al. The impact of multiple metastatic nodal stations on survival in patients with resectable N1 and N2 non-small-cell lung cancer. Ann Thorac Surg, 2008, 86: 1092–1097.CrossRefPubMedGoogle Scholar
- 20.Lally BE, Zelterman D, Colasanto JM, et al. Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database. J Clin Oncol, 2006, 24: 2998–3006.CrossRefPubMedGoogle Scholar